FOXO4

10mg Vial

2 September 2026Updated 2 September 2026

FOXO4

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for FOXO4.

Create free account Member login

Full range of benefits for FOXO4

Disrupts FOXO4–p53 interaction to induce apoptosis in senescent cells

Promotes clearance of senescent cells in preclinical models

Reduces common senescence markers (p16INK4a, SA-β-gal) in studies

Attenuates pro‑inflammatory SASP factor secretion in lab models

Shows selective senolytic activity versus proliferating cells in vitro

Improves measures of tissue function (kidney, muscle, fitness) in aged mice

May aid recovery after genotoxic chemotherapy by removing senescent cells

Modulates p53 localization and apoptotic signaling in senescent cells

Primarily supported by animal and cell data; human effects remain unproven

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(3)Compatible(4)Monitor(4)Avoid(5)

Works exceptionally well with this peptide

Dasatinib

Tyrosine kinase inhibitor that has been used in combination senolytic protocols and can enhance clearance of senescent cells by complementary mechanisms when given with FOXO4-based peptides.

Quercetin

Flavonoid senolytic that targets different pro-survival pathways in senescent cells and can increase overall senolytic efficacy when co-administered with FOXO4 peptides.

BCL-2 family inhibitors (navitoclax)

Inhibitors of anti-apoptotic BCL-2 proteins can synergize with FOXO4-mediated disruption of senescent cell survival to promote apoptosis, potentially increasing senescent-cell clearance.

All interaction categories

Synergistic (3)

Dasatinib: Tyrosine kinase inhibitor that has been used in combination senolytic protocols and can enhance clearance of senescent cells by complementary mechanisms when given with FOXO4-based peptides.
Quercetin: Flavonoid senolytic that targets different pro-survival pathways in senescent cells and can increase overall senolytic efficacy when co-administered with FOXO4 peptides.
BCL-2 family inhibitors (navitoclax): Inhibitors of anti-apoptotic BCL-2 proteins can synergize with FOXO4-mediated disruption of senescent cell survival to promote apoptosis, potentially increasing senescent-cell clearance.

Compatible (4)

Metformin: AMPK-activating geroprotective agent with no expected direct pharmacokinetic interaction and generally compatible with FOXO4-based senolytic approaches.
Atorvastatin: HMG-CoA reductase inhibitor for cardiovascular risk management with no known direct interaction with peptide senolytic therapies.
Cholecalciferol (vitamin D): Vitamin D supplementation is neutral with respect to FOXO4 activity and may support musculoskeletal health during senolytic therapy.
Lisinopril: ACE inhibitor used for blood pressure control that has no anticipated direct interaction with peptide-based senolytics.

Monitor (4)

Anticoagulants (warfarin, DOACs): Monitor coagulation and bleeding risk because senescent-cell apoptosis and tissue remodeling may transiently affect hemostasis and procedural bleeding.
Immunosuppressants (tacrolimus, cyclosporine): Monitor infection risk and drug levels as altered immune clearance of apoptotic cells or inflammatory shifts could necessitate immunosuppressant dose adjustment and increase infection susceptibility.
Cytotoxic chemotherapies (e.g., doxorubicin, platinum agents): Closely monitor bone marrow function and organ toxicity when given concomitantly due to potential additive apoptotic effects and increased marrow suppression.
Systemic corticosteroids (prednisone): Monitor for masked inflammatory responses, infection risk, and glycemic effects because corticosteroids can alter immune handling of apoptotic cells and systemic response to senolysis.

Avoid (5)

Pregnancy and lactation: Avoid or carefully evaluate use because there are no adequate safety data and potential risks to the fetus or infant are unknown with senolytic peptide therapy.
Antiplatelet agents (aspirin, clopidogrel): Use caution due to increased risk of bleeding when tissue remodeling and inflammatory responses follow senescent-cell apoptosis.
Live attenuated vaccines: Exercise caution because immune modulation after senolytic therapy may alter vaccine responses and increase theoretical risk from live vaccines.
Strong CYP3A4 inhibitors/inducers (when co-administering small-molecule senolytics like dasatinib): Carefully evaluate interactions because CYP3A4 modulators can markedly change exposure of co-administered small-molecule senolytics used in combination protocols, requiring dose adjustment.
Pre-existing severe cytopenias: Use caution and evaluate risk–benefit as FOXO4-mediated senolysis combined with other pro-apoptotic agents may exacerbate neutropenia, anemia, or thrombocytopenia.